The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

NeoGenomics, Inc. (NASDAQ:NEO) is one of the top 10 medical AI companies to buy according to analysts. On July 30, the company announced the launch of NEO PanTracer LBx, a blood-based comprehensive ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

Liquid biopsy’s potential as a diagnostic in cancer is gaining recognition, and its advantages over tissue biopsy in non-small cell lung cancer (NSCLC) were featured in research recently ...

Liquid biopsy vs. tissue biopsy A tissue biopsy is currently the ‘gold standard’ test for diagnosing cancer. It involves a surgical procedure to remove a tissue sample – for example, from a suspicious ...

LONDON--(BUSINESS WIRE)--The global liquid biopsy market is expected to grow by USD 4.02 billion as per Technavio. This marks a significant market slow down compared to the 2019 growth estimates ...